Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum

Next Previous
Trial Profile

Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary) ; Atazanavir (Primary) ; Atazanavir/cobicistat (Primary) ; Cobicistat (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Darunavir (Primary) ; Didanosine (Primary) ; Dolutegravir (Primary) ; Efavirenz (Primary) ; Elvitegravir (Primary) ; Emtricitabine (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Fosamprenavir (Primary) ; Indinavir (Primary) ; Lopinavir/ritonavir (Primary) ; Maraviroc (Primary) ; Nelfinavir (Primary) ; Nevirapine (Primary) ; Ritonavir (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Amikacin; Aminosalicylic acid; Bedaquiline; Capreomycin; Clofazimine; Cycloserine; Delamanid; Ethambutol; Ethinylestradiol; Ethionamide; Etonogestrel; Etravirine; Isoniazid; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Pretomanid; Protionamide; Pyrazinamide; Raltegravir; Rifampicin; Rilpivirine; Terizidone; Tipranavir; Zidovudine
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms IMPAACT

    • Most Recent Events

    • 12 Feb 2022 Results (n=29) assessing pharmacokinetic, safety, and birth outcomes with TAF 25 mg with a boosted protease inhibitor (PI) in pregnant women living with HIV (PWLH) published in the JAIDS
    • 02 Nov 2021 Results (N=11) of an analysis assessing evaluate the pharmacokinetics and safety of atazanavir and cobicistat (FDC) in pregnant women with HIV-1 published in the JAIDS
    • 15 Aug 2021 Results of an analysis assessing the etonogestrel/antiretroviral therapy drug-drug interactions, and the effects of etonogestrel on ritonavir-boosted-atazanavir, ritonavir-boosted-lopinavir, and efavirenz pharmacokinetics published in the Contraception
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top